Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - April 1, 2025 765 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-1 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Genetic Testing for Bladder Cancer: What People With Cancer and Their... March 23, 2023 Men’s skin cancer rates increase by 50% over decade June 24, 2021 FDA Proposes Rule Prohibiting Menthol Cigarettes June 27, 2022 Aggressive Prostate Cancer Subtype More Common Than Expected July 31, 2018 Load more HOT NEWS ESMO’s Special Consultative Status with United Nations Economic and Social Council... County Denies Immunocompromised Employee’s Request to Work from Home During COVID-19 Adjuvant Pembrolizumab Improves Overall Survival Among Patients with Clear-Cell Renal Cell... 2023 ASCO Annual Meeting Research Round Up: Improving Symptom Monitoring and...
